4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

12th - 13th March, 2020 | ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
CONFERENCE SPEAKERS
Advisors
Stefan Gluck
Stefan Gluck
Vice President,
Celgene, USA



Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer,
Biomunex Pharmaceuticals, France



Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy,
King’s College London, UK



Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer,
Merck Sharp & Dohme, USA



Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Steven F. Schellings
Steven F. Schellings
Associate Director, Cellular Therapy, Account Management,
Novartis, USA



Stefan Gluck
Stefan Gluck
Vice President,
Celgene, USA



Bruno Tullia
Bruno Tullia
Assistant Professor,
UPMC Hillman Cancer Center, USA



Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy,
University of Nottingham, UK



Junjian Liu
Junjian Liu
Vice President, Biologics Discovery,
Innovent Biologics, China



Sebastien Tabruyn
Sebastien Tabruyn
CSO,
TransCure bioServices SAS, France



Eugene Zhukovsky
Eugene Zhukovsky
Chief Scientific Officer,
Biomunex Pharmaceuticals, France



Andrew Sewell
Andrew Sewell
Professor, Division of Infection and Immunity,
Cardiff University, UK


Sewell group research is focused around T-cell ligands and the receptors that recognise them during infection, autoimmune disease, transplant rejection and cancer immunotherapy. The alpha-beta TCR can exploit the MHC class I presentation pathway to target any cell based on its expression of any protein in vivo, thereby accessing a far greater range of targets than are accessible to monoclonal antibodies. Our newer studies indicate that alpha-beta and gamma-delta TCRs can target neoplasms by other, novel mechanisms. We aim to exploit these findings to generate new, broad-spectrum cancer therapeutics.


Ann White
Ann White
Senior Principal Scientist,
UCB Celltech, UK



Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy,
King’s College London, UK



Scott Durum
Scott Durum
Head, Cytokines and Immunity,
NIH


Scott K. Durum PhD trained at Oak Ridge, National Jewish Denver and Yale before coming to the National Cancer Institute, National Institutes of Health where he is chief of the Section of Cytokines and Immunity. His lab has studied the role of cytokines in the immune system, with a long interest in the IL-7 pathway which is essential for T lymphocyte development and survival. His lab together with collaborators found gain-of-function mutations in the IL-7 receptor that drive acute lymphoblastic leukemia, the most common cancer in children. They are currently studying the mechanism of leukemogenesis and developing therapeutics to target the pathway. He also plays in NIH’s band, the Affordable Rock n Roll Act.


Ali Roghanian
Ali Roghanian
Assistant Professor, Cancer Immunology,
University of Southampton, UK



Jenny Schroeder
Jenny Schroeder
Group Leader, Global R&D Discovery Solutions,
Lonza, Germany



Soldano Ferrone
Soldano Ferrone
Professor of Surgery,
Harvard University, USA



Thomas Tan
Thomas Tan
Vice President, Immunology,
Elstar Therapeutics, USA



Sheeba Irshad
Sheeba Irshad
CRUK Clinician Scientist & Honorary Medical Oncologist,
Guy’s Hospital, UK



David Gilham
David Gilham
Vice President, R&D,
Celyad, UK



John Maher
John Maher
Chief Scientific Officer,
Leucid Bio, UK



Angela Vasaturo
Angela Vasaturo
Senior Field Application Scientist ,
Ultivue, UK



Aude De Gassart
Aude De Gassart
Director of Preclinical Research ,
ImCheck Therapeutics, France



Asher Nathan
Asher Nathan
CEO ,
NeoTX Therapeutics, Israel



Imke Mulder
Imke Mulder
Research Director ,
4D Pharma Research, UK



Will Arends
Will Arends
Chartered (UK) and European Patent Attorney,
Marks & Clerk, UK



Vivian Barak
Vivian Barak
Head, Immunology Lab for Tumor Diagnosis,
Hadassah Medical Center, Israel



Stephen Harper
Stephen Harper
Group Leader, Protein Science,
Immunocore, UK



Markus Zettl
Markus Zettl
Director, Immuno-Oncology ,
Pieris Pharmaceuticals, Germany



Debiprasad Roy
Debiprasad Roy
Senior Director, R&D Technology Platforms,
Allogene Therapeutics, USA



Danny Wells
Danny Wells
Principal Investigator,
Parker Institute for Cancer Immunotherapy, USA